Ascendis Pharma A/S (ASND)
After hours:
- Simply Wall St.
Ascendis Pharma First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Ascendis Pharma ( NASDAQ:ASND ) First Quarter 2024 Results Key Financial Results Revenue: €95.9m (up 186% from 1Q...
- GlobeNewswire
Ascendis Pharma Reports First Quarter 2024 Financial Results
— Rollout of YORVIPATH® initiated in Germany and Austria, with an estimated 55 doctors writing prescriptions and ~100 patients receiving commercial product as of March 31 — TransCon™ PTH (palopegteriparatide) PDUFA date of May 14, 2024, for adults with hypoparathyroidism. If approved, U.S. launch planned in Q3 — TransCon CNP (navepegritide) pivotal ApproaCH Trial on track for topline results in Q4 2024 — SKYTROFA® Q1 revenue more than doubled year-over-year to €65 million; Q1 operating expenses
- GlobeNewswire
Ascendis Pharma to Report First Quarter 2024 Financial Results and Provide Business Update on May 2, 2024
COPENHAGEN, Denmark, April 25, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it will report first quarter 2024 financial results and provide a business update on Thursday, May 2, 2024, after the close of the U.S. financial markets. Ascendis Pharma will also host a conference call and live webcast on May 2, 2024, at 4:30 p.m. Eastern Time (ET) to discuss its first quarter 2024 financial results. Those who would like to participate may access the live webcast here, or
